Clinical and Experimental Dermatology最新文献

{"title":"Predictive Factors of Eczematous Eruptions and Candidiasis during anti IL-17 Treatment in Psoriatic Patients: a Multicenter Italian Real-life Experience in Lazio Region.","authors":"Giacomo Caldarola, Eleonora De Luca, Simone Amato, Alfredo Belcastro, Nicoletta Bernardini, Luca Bianchi, Annunziata Dattola, Clara De Simone, Gaia Moretta, Sabatino Pallotta, Ketty Peris, Antonio Richetta, Raimondo Rossi, Nevena Skroza, Marco Galluzzo","doi":"10.1093/ced/llaf271","DOIUrl":"https://doi.org/10.1093/ced/llaf271","url":null,"abstract":"<p><strong>Background: </strong>Anti-interleukin (IL)-17 therapies have revolutionized psoriasis treatment, offering excellent clinical outcomes and safety profiles. However, these drugs have been associated with class-specific side effects, Candida infections and eczematous reactions.</p><p><strong>Objective: </strong>To assess the frequency of Candida infections and cutaneous eczematous eruptions in patients with plaque psoriasis treated with secukinumab, ixekizumab, brodalumab, or bimekizumab and to identify risk factors.</p><p><strong>Methods: </strong>A multicenter, retrospective, observational study was conducted involving patients with plaque psoriasis treated with anti-IL-17 biologics at five outpatient clinics in Lazio, Italy. Demographic, clinical data, treatment characteristics, and adverse events were analyzed. Cox regression models were used to identify factors associated with the occurrence of these adverse events.</p><p><strong>Results: </strong>Among 1075 patients, 34 (3.2%) developed eczema, and 36 (3.3%) had candidiasisTherapy was discontinued in 78.1% of eczema cases and 50% of candidiasis cases. Multivariate analysis showed that ixekizumab (HR 3.45, p = 0.050) and atopic history (HR 5.43, p = 0.023) were correlated with eczema, while bimekizumab (HR 23.30, p = 0.002) was strongly associated with candidiasis.</p><p><strong>Conclusions: </strong>Anti-IL-17 therapies show varying risks of eczema and candidiasis. Personalized strategies, regular monitoring, and prophylactic measures are essential to improve outcomes.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511626","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Anifrolumab for treatment of cutaneous lupus erythematosus: a 10-case series.","authors":"Elena Hernández-Salas, Celia Horcajada-Reales, Carlos Palomar-Prieto, Laura Fernández-de la Fuente, Sara Herrero-Ruiz, Ana Martínez-Lauwers Dolz, Alberto Romero-Maté","doi":"10.1093/ced/llaf272","DOIUrl":"https://doi.org/10.1093/ced/llaf272","url":null,"abstract":"<p><p>Anifrolumab is a monoclonal antibody that targets the type I interferon receptor subunit 1. It was approved for the treatment of systemic lupus erythematosus by the FDA in 2021 and by the EMA in 2022. Although phase III clinical trials reported a statistically significant improvement in skin lesions, it has not yet been approved for the treatment of cutaneous lupus erythematosus. We present a case series that includes 10 patients with cutaneous lupus erythematosus who demonstrated a rapid and sustained response to anifrolumab.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Real-life experience using topical nitrogen mustard gel in the treatment of stage IA-IVA2 mycosis fungoides: a single centre experience of 66 patients.","authors":"Farrah S Bakr, Rita Entsua Mensah, Claire Lusted, Fiona Child, Bjorn Thomas, Sean Whittaker, Stephen Morris, Van Sim, Elisabeth Mary Wain","doi":"10.1093/ced/llaf265","DOIUrl":"https://doi.org/10.1093/ced/llaf265","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511628","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"How to recognize a difficult squamous cell carcinoma? A retrospective analysis of clinically and dermatoscopically misdiagnosed tumors.","authors":"Katarzyna Korecka, Paweł Pietkiewicz, Bengü Nisa Akay, Iulia Badiu, Enzo Errichetti, Konstantinos Liopyris, Caterina Longo, Ashfaq Marghoob, Cristian Navarrete-Dechent, John Paoli, Verce Todorovska, Aimilios Lallas","doi":"10.1093/ced/llaf255","DOIUrl":"https://doi.org/10.1093/ced/llaf255","url":null,"abstract":"<p><strong>Background: </strong>Squamous cell carcinoma (SCC) is usually non-pigmented in fair-skinned individuals and has to be discriminated from other non-pigmented tumors. Although the dermatoscopic features of SCC are well-known, some SCCs are challenging to recognize even with dermatoscopy.</p><p><strong>Objectives: </strong>To investigate clinical and dermatoscopic features responsible for an inaccurate clinical diagnosis of invasive SCC and potential clues that could help in their recognition.</p><p><strong>Methods: </strong>Retrospectively screening our institutional database, we screened for clinically misdiagnosed SCCs within a time period of 10 years (2013 to 2023). 10 expert dermatoscopists were presented a series of clinical and dermatoscopic images of misdiagnosed invasive SCCs.</p><p><strong>Results: </strong>Seventy-three SCCs from 73 patients (55 males and 18 females) aged 37 to 97 years old (mean age 78.8 years) were included. Most tumors were located on the cheek (20,5%), followed by forehead (16,4%), nose (12,32%) and scalp (12,32%). Thirty-seven SCCs were misdiagnosed as BCC, 15 as actinic keratosis, 10 as irritated seborrheic keratosis, 7 as Bowen disease, 2 as viral wart and 2 as cutaneous horn. White scales and keratin were voted as the main features that might have helped in the accurate clinical diagnosis of the included SCCs (29/73).</p><p><strong>Conclusions: </strong>The dermatoscopic characteristics of invasive SCC might overlap with other tumors. In challenging tumors, white scale and keratin might guide the accurate recognition of invasive SCC.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505020","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"A multicentre qualitative study of patient perceptions and experiences with secondary intention wound healing and skin grafting (PERCEIVE) across the United Kingdom and the Republic of Ireland.","authors":"Puo Nen Lim, Jenny Caesar, Garret O'Connell, William Thomas Nicholas Hunt, Mohanad Aldiwani, Dushyanth Gnanappiragasam, Mun-Wai Lam, Gregory Parkins, Martin Porter, Rachel Abbott, Michael O'Connell, Thomas Oliphant, Simon Tso, Aaron Wernham","doi":"10.1093/ced/llaf263","DOIUrl":"https://doi.org/10.1093/ced/llaf263","url":null,"abstract":"<p><strong>Background: </strong>For skin surgical sites that cannot be closed directly, alternative methods such as secondary intention healing (SIH) and full thickness skin grafting (FTSG) are utilised. Published literature on wound closure methods are primarily focused on objective outcomes such as healing time, cosmesis and postoperative complications. There is a paucity of literature exploring patient experiences with these wound reconstructive modalities.</p><p><strong>Objectives: </strong>To explore patient experiences of skin surgery with SIH and FTSG.</p><p><strong>Methods: </strong>This is a multi-centre interview based qualitative study involving 6 sites across the UK and the Republic of Ireland. One-to-one semi-structured interviews were conducted with patients who had an open surgical wound (for SIH) or a FTSG following excision of keratinocyte cancers. Patients were interviewed twice: one within a week post-surgery and another three months later. Audio recordings of interviews were transcribed verbatim and analysed using the six-step thematic analysis method by Braun and Clarke.</p><p><strong>Results: </strong>24 patients (19 males and 5 females; 12 SIH and 12 FTSG) with histologically confirmed keratinocyte cancers took part in the first interview. Age ranged 44 to 88 years. There were 22 completed second round interviews. Four key themes emerged: perception of overall quality of care (non-clinical), pre-operative experience, intra-operative experience, and post-operative experience. The first time patients visualised their surgical wound when changing dressing was a critical moment in their journey.</p><p><strong>Conclusion: </strong>Patient experiences with skin surgery are highly individualised. Addressing their information needs, including those related to ancillary, and involving them in shared decision-making can enhance patient satisfaction.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511570","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Finasteride use and suicide attempts through self-poisoning: A case-control study.","authors":"Ida M Heerfordt, Annika Magdalena Rhomberg-Kauert, Kim Peder Dalhoff, Morten Tulstrup, Henrik Horwitz","doi":"10.1093/ced/llaf268","DOIUrl":"https://doi.org/10.1093/ced/llaf268","url":null,"abstract":"<p><p>This study investigated the potential link between finasteride, commonly used for hair loss, and suicide attempts via self-poisoning. It was motivated by concerns over unanticipated psychological side effects like suicidality identified in post-trial adverse event reports. We used data from multiple Danish health registry to assess males reported for suicidal intent poisoning. Each case was matched with ten controls based on age, sex, and residential municipality. We collected data on finasteride prescriptions up to one year before the index date, which was the date of the suicide attempt for cases and the inclusion date for controls. The study included 3,366 cases and 33,660 controls. Adjustments were made for diagnosed bipolar disorder and schizophrenia, as well as occupational status. The analysis showed no link between finasteride use and suicide attempt risk, with an unadjusted odds ratio of 1.03 (95% CI: 0.56-1.88) and an adjusted odds ratio of 0.88 (95% CI: 0.45-1.71).</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511577","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Infectious Disease.","authors":"Anna Wolinska, Maria McWalter, Padraig McGettrick, Emma Shudell","doi":"10.1093/ced/llaf252","DOIUrl":"https://doi.org/10.1093/ced/llaf252","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505022","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Well circumscribed eroded lesions on the palms of a middle-aged woman.","authors":"Louise L K St Aimee, Paul Craig, Hannah E Wainman","doi":"10.1093/ced/llaf260","DOIUrl":"https://doi.org/10.1093/ced/llaf260","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Need for National Standards in Documenting 2WW Skin Cancer Clinics.","authors":"Matus Kalavsky, Shafiah Muna Abdul Gafoor, Elizabeth Orrin","doi":"10.1093/ced/llaf266","DOIUrl":"https://doi.org/10.1093/ced/llaf266","url":null,"abstract":"","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144511630","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Multi-centre, prospective, observational clinical registry of paediatric and adult patients with vitiligo on phototherapy, or novel topical/systemic immune-modulatory therapies.","authors":"Viktoria Eleftheriadou, Emma Rush, Lorraine Jacques","doi":"10.1093/ced/llaf249","DOIUrl":"https://doi.org/10.1093/ced/llaf249","url":null,"abstract":"<p><p>Vitiligo is the most common depigmentation disorder affecting around 1% of the population worldwide. Currently, no national or international registry for patients with vitiligo exists. Individual dermatologists maintain a descriptive database of such patients, which involves patients in one centre. In addition, such single centre registries do not aim to establish short- and long-term safety (pharmacovigilance) and effectiveness of vitiligo therapies. As an initial step for the development of a national UK registry for vitiligo patients, development of a pilot multi-centred registry in the UK is needed. This pilot study is being developed in collaboration with the British Association of Dermatologists (BAD). VIRTUAL-UK (VItiligo RegisTry for adUlts And children) assesses treatment effectiveness and safety as well as treatment impact on quality of life in children and adults with vitiligo, who receive phototherapy, novel topical and/or systemic immuno-modulatory therapies. Such a registry will ultimately inform treatment guidelines, provide pharmacogenetic and pharmacodynamic research data, help answer questions on skin cancer risk for vitiligo patients who receive prolonged phototherapy courses, especially regarding high cumulative exposures in children with less deeply pigmented skin, and help to identify those patients likely to experience rapid disease progression, ultimately improving and personalising patient care. With novel topical and oral immunomodulatory therapies having just entering vitiligo clinical practice, the timing is ideal to harness the high-quality data collection offered by the UK NHS.</p>","PeriodicalId":10324,"journal":{"name":"Clinical and Experimental Dermatology","volume":" ","pages":""},"PeriodicalIF":3.7,"publicationDate":"2025-06-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144505023","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}